Allogene Therapeutics Inc
$ 1.88
-7.84%
05 Jun - close price
- Market Cap 648,891,000 USD
- Current Price $ 1.88
- High / Low $ 2.02 / 1.87
- Stock P/E N/A
- Book Value 1.14
- EPS -0.77
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.52 %
- 52 Week High 4.46
- 52 Week Low 0.98
About
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Analyst Target Price
$8.35
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-12 | 2025-11-06 | 2025-08-13 | 2025-05-13 | 2025-03-13 | 2024-11-07 | 2024-08-07 | 2024-05-13 | 2024-03-14 | 2023-11-02 | 2023-08-02 |
| Reported EPS | -0.18 | -0.17 | -0.19 | -0.22 | -0.28 | -0.28 | -0.27 | -0.32 | -0.38 | -0.43 | -0.37 | -0.53 |
| Estimated EPS | -0.18 | -0.2255 | -0.23 | -0.27 | -0.29 | -0.3234 | -0.33 | -0.35 | -0.41 | -0.45 | -0.52 | -0.59 |
| Surprise | 0 | 0.0555 | 0.04 | 0.05 | 0.01 | 0.0434 | 0.06 | 0.03 | 0.03 | 0.02 | 0.15 | 0.06 |
| Surprise Percentage | 0% | 24.612% | 17.3913% | 18.5185% | 3.4483% | 13.4199% | 18.1818% | 8.5714% | 7.3171% | 4.4444% | 28.8462% | 10.1695% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALLO
2026-06-01 20:40:21
David Chang, co-founder of Allogene Therapeutics Inc., is stepping down as CEO at the end of June. This leadership change occurs as the company is conducting a critical clinical trial for a potential regulatory approval of its lymphoma treatment. The San Francisco Business Times is also seeking nominations for its C-Suite Leaders Awards.
2026-05-30 20:39:45
Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the board, bringing extensive oncology and cell therapy experience to the role. His compensation package includes a base salary of $680,000, a significant stock option and RSU package, and eligibility for severance benefits, aligning his interests with shareholders.
2026-05-30 18:39:53
Allogene Therapeutics, Inc. has common stock subject to a lock-up agreement that ends on May 30, 2026. The lock-up period began on April 14, 2026, and prevents the company's directors and executive officers from disposing of or hedging common stock or related securities for 45 days without underwriter consent. This measure is standard for certain offerings to ensure market stability post-issuance.
2026-05-30 12:22:00
Zachary Roberts, currently EVP of R&D and CMO of Allogene Therapeutics Inc. (NASDAQ:ALLO), will take over as president and CEO on July 1. He will also join the board. David Chang, a co-founder who has led the company for eight years, will remain on the board.
2026-05-30 00:09:40
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a lock-up agreement that ends on May 30, 2026. These units were locked up for 46 days starting on April 14, 2026. The agreement restricts the disposal or hedging of common stock or convertible securities by the company, its directors, and executive officers for a specified period after the prospectus supplement date.
2026-05-29 23:09:40
Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently the executive vice president of R&D and chief medical officer, will also join the board. His compensation package includes a significant stock option and RSU grant, aligning his incentives with shareholder interests while Allogene focuses on advancing its allogeneic cell therapies for cancer.
